ClinicalTrials.gg
Status unknownNCT05400876Updated Feb 14, 2023

To Evaluate the Safety and Efficacy of TQB2618 Injection Combined With Penpulimab in the Treatment of Patients With Relapsed and Refractory Lymphoma

A Phase 1/2 interventional study of TQB2618 injection and Penpulimab injection in Relapsed/Refractory Lymphoma, sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-02-14.

Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (part of Sino Biopharmaceutical Limited) · Phase 1/2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Jun 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
92
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 275 studies in Lymphoma with a site in China — 102 open to participants now, 118 under way, 10 of them phase 3. Lymphoma · China.

Planned enrollment
71st of 232
92 · median 47
Started
2022
with 35 others
Phase 1/2
55 of 275
24 open now
Registered
157th of 275
by date

Among the 275 studies in Lymphoma with a site in China, this one is the 71st largest by planned enrollment of the 232 interventional ones that give a count, is one of 36 that started in 2022, is one of 55 in phase 1/2, and was the 157th registered.

Lymphoma

3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.

Browse Lymphoma studies →

Open to participants now

102 of the 275 studies in Lymphoma with a site in China are open now. Recruiting first, the newest first:

97 more — sign in →

All 102 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Lymphoma with a site in China, or all of them as a file.
02

Study summary

This is a two-phase, open-label Phase Ib clinical trial to evaluate the safety and efficacy of TQB2618 injection combined with Penpulimab in patients with relapsed and refractory lymphoma

03

Conditions studied

  • Relapsed/Refractory Lymphoma

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 1 Subjects with proven with lymphoma and with disease progression during or after the last treatment or no objective response confirmed after adequate treatment.
  • 2 Cohort 1: Subjects with Classical Hodgkin lymphoma (cHL) who had previously received at least twice systemic therapy and are resistant to or PD-L1.
  • 3 Cohort 2: Subjects with B lymphocyte non-Hodgkin lymphoma (B-NHL) who had previously received at least twice systemic therapy containing anti-CD20-targeted therapy.
  • 4 Cohort 3:Subjects with T lymphocyte non-Hodgkin lymphoma (T-NHL) who had previously received at least one systemic therapy.
  • 5 Subjects with as defined by Lugano2014.
  • 6 Aged 18-75 years ; (ECOG) score:0 \~ 1; Expected survival ≥3 months.
  • 7 Laboratory indicators meet the requirements.
  • 8 Subjects voluntarily joined the study and signed the form.
  • 9 Non-pregnant or non-breastfeeding women; Negative pregnancy subjects.

Exclusion criteria

Exclusion Criteria:

  • 1 Subjects who have developed or is currently suffering from other within 3 years, with the exception of cured skin basal cell carcinoma and cervical carcinoma in situ.
  • 2 Subjects who have not recovered to ≤ (CTCAE) Grade 1 due to the adverse event of prior therapy.
  • 3 Subjects with significant surgery or significant traumatic injury within 28 days before first injection (excluding needle or endoscopic biopsy).
  • 4 Subjects with long-term unhealed wounds or fractures.
  • 5 Subjects with the high risk of bleeding or bleeding history or subjects with bleeding event (≥Common Terminology Criteria for Adverse Events Grade 3) within 4 weeks before first injection.
  • 6 Subjects with arterial/venous thrombosis within 6 months.
  • 7 Subjects with a history of psychotropic substance abuse who cannot be withdrawn or have mental disorders.
  • 8 Subjects with any severe and/or uncontrolled disease.
  • 9 subjects with lymphoma originating from Central Nervous System, high-grade B-cell lymphoma or hemophagocytic syndrome during screening period.
  • 10 Subjects with violating Central Nervous System (CNS) .
  • 11 Subjects with hematopoietic stem cell transplantation.
  • 12 Subjects with autologous hematopoietic stem cell transplantation or Chimeric Antigen Receptor T-Cell Immunotherapy(CAR-T) within 3 months before first injection.
  • 13 Subjects with other factors that might cause the study to be terminated halfway per the judgement of the investigator.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
92 participants (estimated)

Study arms

  • Experimental
    TQB2618 injction+penpulimab injection

    TQB2618 injection with penpulimab injection, 21 days as a treatment cycle

    Drug: TQB2618 injection · Drug: Penpulimab injection

Interventions

  • TQB2618 injection is an inhibitor of T cell immunoglobulin and mucin domain-containing protein 3 (TIM3)

  • Penpulimab is an inhibitor of programmed cell death protein 1 (PD-1)

06

What researchers measure

Primary outcomes

  1. dose limiting toxicity/DLT

    The relevant adverse reactions occurred within the first cycle

    Time frame: From the first injection up to 3 weeks

  2. recommended phase II dose/RP2D

    The dose of TQB2618 injection which is recommended to use during phase II clinical trial

    Time frame: From the first injection up to 6 weeks

  3. Overall response rate (ORR) based on 2014 Lugano

    Percentage of participants achieving complete response (CR) and partial response (PR).

    Time frame: From the first injection up to 96 weeks

Secondary outcomes

  1. complete remission rate/CRR

    Percentage of participants achieving complete response

    Time frame: From the first injection up to 96 weeks

  2. Disease control rate/DCR

    Percentage of participants achieving complete response (CR) and partial response (PR) and stable disease (SD).

    Time frame: From the first injection up to 96 weeks

  3. Duration of Response (DOR)

    The time when the participants first achieved CR or PR to disease progression or death from any cause.

    Time frame: From the first injection up to 120 weeks

  4. Progression-free survival (PFS)

    PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause. cause. cause. PFS defined as the time from randomization until the first documented progressive disease (PD) or death from any cause.

    Time frame: Up to 96 weeks

  5. Overall survival/OS

    OS defined as the time from randomization until the death from any cause

    Time frame: From date of randomization until the death from any cause, assessed up to 120 weeks

  6. Peak time/Tmax

    The time to peak concentration

    Time frame: Cycle 1 day 1 Before administration, 30 minuets,4,8,24,48,144,312 hours after minuets, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, Cycle 7 day 1, Cycle 8 day 1 before and 30 minutes after administration.each cycle 21 days

  7. Peak concentration (Cmax)

    Maximum plasma drug concentration

    Time frame: Cycle 1 day 1 Before administration, 30 minuets,4,8,24,48,144,312 hours after minuets, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, Cycle 7 day 1, Cycle 8 day 1 before and 30 minutes after administration.(each cycle 21 days)

  8. Half-life /T1/2

    The time it takes for the drug's concentration in the body to drop by half

    Time frame: Cycle 1 day 1 Before administration, 30 minuets,4,8,24,48,144,312 hours after minuets, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, Cycle 7 day 1, Cycle 8 day 1 before and 30 minutes after administration.(each cycle 21 days)

  9. Receptor Occupancy/RO

    The extent to which antibody drugs occupy cell surface targets

    Time frame: Cycle 1 day 1, Cycle 2 day 1, Cycle 3 day 1, Cycle 4 day 1, Cycle 5 day 1, Cycle 6 day 1, Cycle 7 day 1, Cycle 8 day 1 before administration and 30 minutes after administration and the day of disease progression(each cycle 21 days)

  10. Incidence of Anti-Drug antibody and neutralizing antibodies

    The incidence of anti-drug antibody and neutralizing antibodies after administration of TQB2618 and penpulimab

    Time frame: Cycle 1 day 1, Cycle 2 day 1, Cycle 4 day 1, Cycle 8 day 1,before administration and 30, 90 days after the last administration(each cycle 21 days)

  11. Adverse event rate

    The occurrence of all adverse events (AEs), serious adverse events (SAEs) and treatment-related adverse events (TEAEs).

    Time frame: Baseline up to 96 weeks

07

Study locations

1 of 1 sites recruiting
  • Sichuan Cancer Hospital
    Chengdu, Sichuan 610042, China
    Recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for May 2023, 11 months after the start.

Of 66 industry-sponsored phase 1/2 interventional studies under Lymphoma, half reached primary completion within 65 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 87. This study's planned 11 months is below that.

Counting every sponsor, half of 143 studies reached it within 74 months; a quarter within 48 and three quarters within 111.

How these figures are worked out, and which studies are left out of them.

Registered
May 16, 2022
First posted
Jun 2, 2022
StartActual
Jun 9, 2022
Primary completionEst.
May 2023
CompletionEst.
Oct 2023
Last update
Feb 14, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 14, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05400876
Responsible party
Sponsor
First posted
Jun 2, 2022
Start date
Jun 9, 2022
Primary completion
May 2023 (estimated)
Completion
Oct 2023 (estimated)
Last update
Feb 14, 2023

Study contacts

Tongyu Lin, Doctor
Contact
tongyulin@hotmail.com
18108243837

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Anti-TIM-3 Monoclonal Antibody TQB2618 · Penpulimab

Start the discussion